CSIMarket
 


Vericel Corporation  (VCEL)
Other Ticker:  
 
 

VCEL's Income from Cont. Operations Growth by Quarter and Year

Vericel's Income from Cont. Operations results by quarter and year




VCEL Income from Cont. Operations (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December 12.99 5.92 4.54 12.22
III Quarter September -3.66 -6.58 -4.93 3.62
II Quarter June -5.02 -8.96 -3.79 -8.27
I Quarter March -7.50 -7.09 -3.29 -4.71
FY   -3.19 -16.71 -7.47 2.86



VCEL Income from Cont. Operations fourth quarter 2023 Y/Y Growth Comment
Vericel Corporation reported Income from Cont. Operations surge of 119.48% year on year in the fourth quarter 2023, to $ 12.99 millions, this is lower than Vericel Corporation's recent average Income from Cont. Operations surge of 275.39%.

According to the results reported in the fourth quarter 2023, Vericel Corporation achieved the best Income from Cont. Operations growth in Biotechnology & Pharmaceuticals industry. While Vericel Corporation' s Income from Cont. Operations doubling of 119.48% ranks overall at the positon no. 163 in the fourth quarter 2023.




VCEL Income from Cont. Operations ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December 119.48 % 30.4 % -62.85 % 28.63 %
III Quarter September - - - 4.32 %
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Vericel's fourth quarter 2023 Income from Cont. Operations $ 12.99 millions VCEL's Income Statement
Vericel's fourth quarter 2022 Income from Cont. Operations $ 5.92 millions Quarterly VCEL's Income Statement
New: More VCEL's historic Income from Cont. Operations Growth >>


VCEL Income from Cont. Operations (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - - - 237.57 %
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Income from Cont. Operations fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #0
Healthcare Sector #19
Overall #163

Income from Cont. Operations Y/Y Growth Statistics
High Average Low
1726.48 % 275.39 % -62.89 %
(Dec 31 2018)   (Dec 31 2021)
Income from Cont. Operations fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #0
Healthcare Sector #19
Overall #163
Income from Cont. Operations Y/Y Growth Statistics
High Average Low
1726.48 % 275.39 % -62.89 %
(Dec 31 2018)   (Dec 31 2021)

Income from Cont. Operations by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Vericel's Q/Q Income from Cont. Operations Growth


Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


VCEL's IV. Quarter Q/Q Income from Cont. Operations Comment
IV. Quarter 2023Cyclical Vericel Corporation in the factors loss from continued operations of $ 12.99 millionsCyclical factors seem to have contributed Vericel Corporation's restoration of positive trends, as VCEL clinchesIncome from Cont. Operations of $ 12.99 millions in the IV. Quarter 2023 coming of loss from continued operations-3.66 millions in the third quarter. Vericel Corporation announced in the IV. Quarter 2023 Income from Cont. Operations of $ 12.99 millions compare to loss from continued operations recorded in previos quarter.

Within Biotechnology & Pharmaceuticals industry Vericel Corporation achieved highest sequential Income from Cont. Operations growth. While Vericel's Income from Cont. Operations growth quarter on quarter, overall rank is .


Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


VCEL's IV. Quarter Q/Q Income from Cont. Operations Comment
IV. Quarter 2023Periodic Vericel Corporation in the circumstances loss from continued operations of $ 12.99 millionsPeriodic circumstances seem to have contributed Vericel Corporation's rebound to profitability, as VCEL postIncome from Cont. Operations of $ 12.99 millions in the IV. Quarter 2023 emanate loss from continued operations-3.66 millions in the third quarter. Vericel Corporation announced in the IV. Quarter 2023 Income from Cont. Operations of $ 12.99 millions compare to loss from continued operations recorded in previos quarter.

Within Biotechnology & Pharmaceuticals industry Vericel Corporation achieved highest sequential Income from Cont. Operations growth. While Vericel's Income from Cont. Operations growth quarter on quarter, overall rank is .


Vericel's 12 Months Income from Cont. Operations Growth Year on Year


Income from Cont. Operations TTM Growth

12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
Cumulative Income from Cont. Operations 12 Months Ending $ -3.18 $ -10.25 $ -13.17 $ -17.11 $ -16.71
Y / Y Income from Cont. Operations Growth (TTM) - - - - -
Year on Year Income from Cont. Operations Growth Overall Ranking # # # # #
Seqeuential Income from Cont. Operations Change (TTM) - - - - -
Seq. Income from Cont. Operations Growth (TTM) Overall Ranking # # # # #




Cumulative Income from Cont. Operations growth Comment


Vericel Corporation achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Income from Cont. Operations growth Comment


Vericel Corporation achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Income from Cont. Operations Growth
Biotechnology & Pharmaceuticals Industry Income from Cont. Operations Growth Trends and Statistics
Healthcare Sector Income from Cont. Operations Growth Statistics
Income from Cont. Operations Growth Trends for overall market
VCEL's Income from Cont. Operations Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Income from Cont. Operations Growth
Lowest Ranking Income from Cont. Operations Growth
Income from Cont. Operations Growth for VCEL's Competitors
Income from Cont. Operations Growth for Vericel's Suppliers
Income from Cont. Operations Growth for VCEL's Customers

You may also want to know
VCEL's Annual Growth Rates VCEL's Profitability Ratios VCEL's Asset Turnover Ratio VCEL's Dividend Growth
VCEL's Roe VCEL's Valuation Ratios VCEL's Financial Strength Ratios VCEL's Dividend Payout Ratio
VCEL's Roa VCEL's Inventory Turnover Ratio VCEL's Growth Rates VCEL's Dividend Comparisons



Companies with similar Income from Cont. Operations doubling for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %Income from Cont. Operations for the quarter ending Dec 31 2023
Align Technology inc 196.86%$ 196.862 millions
Alcon inc 190.75%$ 190.746 millions
Dexcom Inc 179.19%$ 179.194 millions
Icon Plc144.76%$ 144.764 millions
Vericel Corporation119.40%$ 119.402 millions
Novartis Ag113.57%$ 113.573 millions
Iqvia Holdings Inc 106.61%$ 106.608 millions
Davita Inc 103.75%$ 103.752 millions
Stryker Corp103.02%$ 103.020 millions
Enzon Pharmaceuticals inc 101.80%$ 101.802 millions
Surgery Partners Inc 100.43%$ 100.429 millions
Corcept Therapeutics Inc88.36%$ 88.364 millions
Intuitive Surgical Inc 81.38%$ 81.378 millions
Astrazeneca Plc81.02%$ 81.020 millions
Tactile Systems Technology Inc 77.49%$ 77.494 millions
Quest Diagnostics Inc76.72%$ 76.724 millions
Dr Reddy s Laboratories Limited76.21%$ 76.206 millions
3m Company74.40%$ 74.401 millions
Electromed Inc 71.34%$ 71.341 millions
Tenet Healthcare Corp66.42%$ 66.423 millions
Alpha Pro Tech Ltd 66.36%$ 66.364 millions
Neurocrine Biosciences Inc 65.96%$ 65.955 millions
Cytek Biosciences Inc 64.76%$ 64.760 millions
United Therapeutics Corporation64.35%$ 64.345 millions
Fonar Corporation64.30%$ 64.296 millions
Select Medical Holdings Corp63.87%$ 63.868 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com